Conditions: Myelodysplastic Syndromes
Keywords: MDS Myelodysplastic Syndromes
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 26
Healthy volunteers: no

Brief summary:
The purpose of this study is to compare the response of patients with Intermediate or High Risk myelodysplastic syndromes (MDS) following treatment with decitabine or azacitidine.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: decitabine intervention 2: azacitidine
Intervention descriptions: intervention 1: decitabine 20 mg/m\^2 /day intravenous (IV) infusion for 5 days every 28 days intervention 2: azacitidine 75 mg/m\^2 /day subcutaneous (SC) injection for 7 days every 28 days

Protocol document: